Biotin-Linked Polyclonal Antibody to Peptidase Inhibitor 3, Skin Derived (PI3)
| Code | Size | Price |
|---|
| LAC849Hu71-200ul | 200ul | £237.00 |
Quantity:
| LAC849Hu71-1ml | 1ml | £547.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Documents
Further Information
Alternative Names:
SKALP; ESI; WAP3; WFDC14; Elafin; Skin-Derived Antileukoproteinase; Cementoin; Elastase-specific inhibitor; WAP four-disulfide core domain protein 14
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Peptidase Inhibitor 3, Skin Derived
Source:
Antibody labeling
Usage:
Western blotting: 0.5-2ug/mL
Immunocytochemistry in formalin fixed cells: 5-20ug/mL
Immunohistochemistry in formalin fixed frozen section: 5-20ug/mL
Immunohistochemistry in paraffin section: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Immunocytochemistry in formalin fixed cells: 5-20ug/mL
Immunohistochemistry in formalin fixed frozen section: 5-20ug/mL
Immunohistochemistry in paraffin section: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Polyclonal Antibody to Peptidase Inhibitor 3, Skin Derived (PI3) | PAC849Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||